文献速递肝病

肝硬化患者经导管与外科主动脉瓣置换术的长期结局:肝病科医生指南

Long-Term Outcomes After Transcatheter and Surgical Aortic Valve Replacement in Patients With Cirrhosis: A Guide for the Hepatologist.
PubMed 文献 · Hepatology · 2020-10-15

该回顾性队列研究对比了105例肝硬化合并重度主动脉瓣狭窄患者接受TAVR(55例)或SAVR(50例)的结局,并纳入无肝硬化对照组及单纯药物治疗的肝硬化患者。结果显示两组短期死亡率相似,MELD评分(而非STS评分)独立预测长期生存;MELD<12时SAVR生存优于TAVR,MELD≥12时两种手术与药物治疗生存相似。

要点

  • TAVR与SAVR在肝硬化患者中短期死亡率相当。
  • MELD评分独立预测TAVR/SAVR术后长期生存。
  • MELD<12者SAVR生存优于TAVR,MELD≥12者手术不优于药物。

核心结论

  • 在部分肝硬化患者中,TAVR和SAVR的短期结局可接受且相当。
  • MELD评分而非STS评分独立预测TAVR和SAVR术后长期生存。
  • MELD评分<12时SAVR是首选术式;MELD评分≥12时两种手术均不优于药物治疗。

研究设计与样本

  • 回顾性队列研究,纳入2008至2016年间105例连续肝硬化合并主动脉瓣狭窄患者,其中TAVR组55例、SAVR组50例。
  • 对照组包括2680例无肝硬化接受TAVR或SAVR的患者,以及17例仅接受药物治疗的肝硬化患者。
  • 中位STS评分为3.8%(1.5, 6.9),中位MELD评分为11.6(9.4, 14.0)。

主要发现

  • TAVR组与SAVR组的院内死亡率分别为1.8%与2.0%,30天死亡率分别为3.6%与4.2%。
  • 中位随访3.8年(95%CI 3.0-6.9)期间共63例(60%)死亡。
  • MELD评分是长期生存的独立预测因子(调整HR 1.13;95%CI 1.05-1.21;P=0.002)。
  • MELD评分<12亚组中,TAVR组中位生存2.8年,SAVR组4.4年(P=0.047)。
  • MELD评分≥12亚组中,TAVR、SAVR和药物治疗的中位生存分别为1.3年、2.1年和1.6年(P=0.53)。

关键数值与推荐

  • MELD评分<12的肝硬化合并主动脉瓣狭窄患者,SAVR是首选术式。
  • MELD评分≥12的患者,TAVR、SAVR与药物治疗的生存相似,手术不优于药物。

临床怎么用

  • 肝病科医生评估肝硬化合并重度主动脉瓣狭窄患者时,应计算MELD评分以辅助选择TAVR或SAVR。
  • 对于MELD评分<12者,优先考虑SAVR;对于MELD评分≥12者,需权衡手术与药物治疗,避免不必要的手术。

局限性

  • 回顾性研究设计,样本量较小(105例肝硬化患者)。
  • 单中心数据,可能存在选择偏倚。
  • 药物治疗组仅17例,结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Hepatologists often determine whether transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) is preferred for patients with cirrhosis and severe aortic stenosis. The goal of this cohort study is to compare outcomes following TAVR and SAVR in patients with cirrhosis to inform the preferred intervention. APPROACH AND RESULTS: Prospectively collected data on 105 consecutive patients with cirrhosis and aortic stenosis who underwent TAVR (n = 55) or SAVR (n = 50) between 2008 and 2016 were reviewed retrospectively. Two control groups were included: 2,680 patients without cirrhosis undergoing TAVR and SAVR and 17 patients with cirrhosis who received medical therapy alone. Among the 105 patients with cirrhosis, the median Society of Thoracic Surgeons score was 3.8% (1.5, 6.9), and the median Model for End-Stage Liver Disease (MELD) score was 11.6 (9.4, 14.0). The TAVR group had similar in-hospital (1.8% vs. 2.0%) and 30-day mortality (3.6% vs. 4.2%) as the SAVR group. During the median follow-up of 3.8 years (95% confidence interval, 3.0-6.9), there were 63 (60%) deaths. MELD score (adjusted hazard ratio, 1.13; 95% confidence interval, 1.05-1.21; P = 0.002) was an independent predictor of long-term survival. In the subgroup of patients with MELD score <12, the TAVR group had reduced survival compared with the SAVR group (median survival of 2.8 vs. 4.4 years; P = 0.047). However, in those with MELD score ≥12, survival after TAVR, SAVR, and medical therapy was similar (1.3 vs. 2.1 vs. 1.6 years, respectively; P = 0.53). CONCLUSION: In select patients with cirrhosis, both TAVR and SAVR have acceptable and comparable short-term outcomes. MELD score, but not Society of Thoracic Surgeons score, independently predicts long-term survival after TAVR and SAVR. For patients with MELD score <12, SAVR is a preferred procedure; however, neither procedure appears superior to medical therapy in patients with MELD score ≥12.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Peeraphatdit TB, Nkomo VT, Naksuk N, et al. Long-Term Outcomes After Transcatheter and Surgical Aortic Valve Replacement in Patients With Cirrhosis: A Guide for the Hepatologist. Hepatology. 2020. PMID: 32080875. doi:10.1002/hep.31193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。